CN113454081B - 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途 - Google Patents

咪唑并吡啶基化合物及其用于治疗增生性疾病的用途 Download PDF

Info

Publication number
CN113454081B
CN113454081B CN202080014118.3A CN202080014118A CN113454081B CN 113454081 B CN113454081 B CN 113454081B CN 202080014118 A CN202080014118 A CN 202080014118A CN 113454081 B CN113454081 B CN 113454081B
Authority
CN
China
Prior art keywords
pyridin
fluoro
imidazo
carboxamide
cyclopropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080014118.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113454081A (zh
Inventor
J·李
S·赵
K·林
A·Y·朴
J·E·金
M·金
I·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Biotherapy Co ltd
Original Assignee
First Biotherapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Biotherapy Co ltd filed Critical First Biotherapy Co ltd
Publication of CN113454081A publication Critical patent/CN113454081A/zh
Application granted granted Critical
Publication of CN113454081B publication Critical patent/CN113454081B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080014118.3A 2019-02-22 2020-02-21 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途 Active CN113454081B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809230P 2019-02-22 2019-02-22
US62/809,230 2019-02-22
PCT/IB2020/051472 WO2020170206A1 (en) 2019-02-22 2020-02-21 Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
CN113454081A CN113454081A (zh) 2021-09-28
CN113454081B true CN113454081B (zh) 2024-08-09

Family

ID=72141573

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080014118.3A Active CN113454081B (zh) 2019-02-22 2020-02-21 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
CN202080014156.9A Active CN113454082B (zh) 2019-02-22 2020-02-21 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080014156.9A Active CN113454082B (zh) 2019-02-22 2020-02-21 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途

Country Status (10)

Country Link
US (4) US20220242861A1 (https=)
EP (2) EP3927706A4 (https=)
JP (2) JP7609790B2 (https=)
KR (2) KR102892275B1 (https=)
CN (2) CN113454081B (https=)
AU (1) AU2020224401A1 (https=)
CA (1) CA3131059A1 (https=)
IL (1) IL285708B2 (https=)
MX (1) MX2021010122A (https=)
WO (2) WO2020170205A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020224401A1 (en) 2019-02-22 2021-10-14 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
CN115968362B (zh) * 2020-08-21 2025-06-13 第一生物治疗股份有限公司 作为pet放射性示踪剂的[18f]-标记的咪唑并吡啶衍生物
US12398156B2 (en) 2020-08-21 2025-08-26 1ST Biotherapeutics, Inc. Compounds for prevention or treatment of neurodegenerative disorders
WO2022064459A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
EP4236950A4 (en) * 2020-10-29 2024-10-23 Merck Sharp & Dohme LLC N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2022165529A1 (en) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Small molecule inhibitors of salt inducible kinases
CN115724839A (zh) * 2021-08-26 2023-03-03 科辉智药生物科技(深圳)有限公司 Sarm1酶活性抑制剂及其应用
EP4499643A4 (en) * 2022-03-25 2026-01-28 1St Biotherapeutics Inc INDAZOLES USED AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND THEIR METHODS OF USE
CN116354959B (zh) * 2023-03-10 2024-04-19 石河子大学 一种N-N桥连噻唑单元的β-咔啉衍生物及其制备方法、应用
CN121941688A (zh) * 2023-10-09 2026-04-28 浙江海正药业股份有限公司 多取代芳基类衍生物及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102480966A (zh) * 2009-06-12 2012-05-30 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
WO2015134171A1 (en) * 2014-03-06 2015-09-11 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020084116A (ko) 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
CN101384586A (zh) * 2006-02-14 2009-03-11 诺华公司 Pi-3激酶抑制剂及其应用方法
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
CA2693232A1 (en) 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
WO2010100144A1 (en) 2009-03-04 2010-09-10 Merck Serono S.A. Fused bicyclic compounds as inhibitors for pi3 kinase
NZ598220A (en) * 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
EA026115B1 (ru) * 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
WO2014004863A2 (en) * 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
EP2892534B8 (en) 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2018017435A1 (en) * 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
WO2018237370A1 (en) * 2017-06-23 2018-12-27 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
AU2018346051B2 (en) 2017-10-02 2022-11-10 1st Biotherapeutics Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
EP3877371A4 (en) * 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
AU2020224401A1 (en) * 2019-02-22 2021-10-14 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102480966A (zh) * 2009-06-12 2012-05-30 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
WO2015134171A1 (en) * 2014-03-06 2015-09-11 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of tbk1

Also Published As

Publication number Publication date
US20210347774A1 (en) 2021-11-11
WO2020170205A1 (en) 2020-08-27
MX2021010122A (es) 2021-09-23
IL285708A (en) 2021-10-31
CN113454081A (zh) 2021-09-28
CN113454082A (zh) 2021-09-28
IL285708B2 (en) 2025-02-01
US20200270246A1 (en) 2020-08-27
AU2020224401A1 (en) 2021-10-14
US11098044B2 (en) 2021-08-24
EP3927706A4 (en) 2022-12-14
JP7609790B2 (ja) 2025-01-07
US12534461B2 (en) 2026-01-27
CA3131059A1 (en) 2020-08-27
KR20210122862A (ko) 2021-10-12
CN113454082B (zh) 2024-07-02
US11802126B2 (en) 2023-10-31
EP3927705A1 (en) 2021-12-29
KR102892275B1 (ko) 2025-11-27
KR20210122861A (ko) 2021-10-12
US20220242861A1 (en) 2022-08-04
JP2022521536A (ja) 2022-04-08
JP2022521537A (ja) 2022-04-08
US20230365557A1 (en) 2023-11-16
WO2020170206A1 (en) 2020-08-27
IL285708B1 (en) 2024-10-01
EP3927706A1 (en) 2021-12-29
EP3927705A4 (en) 2022-12-07

Similar Documents

Publication Publication Date Title
CN113454081B (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
CA2859668C (en) Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
KR101936851B1 (ko) 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체
CN112839937B (zh) 异吲哚啉-1-酮衍生物、其制备方法及其用途
HK1217482A1 (en) Enzyme modulators and therapies
CN102015705A (zh) 稠合的杂环衍生物及其用途
JP2007502820A (ja) Ｎ−置換ピラゾリル−アミジル−ベンズイミダゾリルｃ−Ｋｉｔ阻害剤
JP5722781B2 (ja) 縮合複素環誘導体およびその用途
KR20110045688A (ko) 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
WO2016011979A1 (zh) 2，4-二取代7H-吡咯并[2，3-d]嘧啶衍生物、其制法与医药上的用途
WO2020038460A1 (zh) 一种新型的喹啉衍生物抑制剂
TWI762534B (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物
CN115515589A (zh) Ulk1/2抑制剂及其使用方法
AU2024321427A1 (en) Pharmaceutical compounds and compositions as c-kit kinase inhibitors
TWI793877B (zh) 作為甘油二酯激酶抑制劑的雜環化合物及其用途
KR20230067669A (ko) 2-아미노-3-카르보닐 이미다조피리딘 및 피라졸로피리딘 화합물
JP2012211085A (ja) ヘッジホッグシグナル阻害剤
WO2018157730A1 (zh) 脲取代的芳环连二噁烷并喹唑啉与连二噁烷并喹啉类化合物及其制备方法与应用
CN118976029A (zh) 用于预防或治疗帕金森病或非酒精性脂肪性肝炎的药学组合物
JP2023501324A (ja) イミダゾリジノン類化合物、並びにその調製方法及び使用
WO2021088845A1 (zh) 咪唑烷酮类化合物及其制备方法与应用
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders
HK40058867B (zh) 咪唑幷吡啶基化合物及其用於治疗增生性疾病的用途
CN107793397B (zh) 取代的嘧啶类pi3k抑制剂的光学异构体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058867

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant